Woodline Partners »

Artiva Biotherapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Artiva Biotherapeutics shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Artiva Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Artiva Biotherapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Artiva Biotherapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $4.4M 283k 15.45

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Artiva Biotherapeutics

RA Capital Management
5AM Venture Management
VR Adviser
venBio Partners
Capital World Investors
BlackRock
Franklin Resources
Geode Capital Management
Samsara BioCapital
Woodline Partners
Northern Trust
Citadel Advisors
Alyeska Investment Group
Charles Schwab Investment Management
Bank of New York Mellon

View all funds holding Artiva Biotherapeutics